The current investment will ramp up the company’s R&D of multi-specific therapeutics.
Eli Lilly intends to recruit biochemist and biologists to support its R&D for multi-specific drugs that can treat diseases in many ways at once in its Indianapolis and San Diego biotechnology facilities.
Lilly Biotechnology Discovery Research vice president Tom Bumol said they can now engineer new therapies where one medicine essentially provides the benefit of two.
"This could produce real benefits for patients, healthcare professionals and payors," Bumol said.